Association of four DNA polymorphisms with acute rejection after kidney transplantation
(2008) In Transplant International 21(9). p.879-891- Abstract
- Renal transplant outcomes exhibit large inter-individual variability, possibly on account of genetic variation in immune-response mediators and genes influencing the pharmacodynamics/pharmacokinetics of immunosuppressants. We examined 21 polymorphisms from 10 genes in 237 de novo renal transplant recipients participating in an open-label, multicenter study [Cyclosporine Avoidance Eliminates Serious Adverse Renal-toxicity (CAESAR)] investigating renal function and biopsy-proven acute rejection (BPAR) with different cyclosporine A regimens and mycophenolate mofetil. Genes were selected for their immune response and pharmacodynamic/pharmacokinetic relevance and were tested for association with BPAR. Four polymorphisms were significantly... (More)
- Renal transplant outcomes exhibit large inter-individual variability, possibly on account of genetic variation in immune-response mediators and genes influencing the pharmacodynamics/pharmacokinetics of immunosuppressants. We examined 21 polymorphisms from 10 genes in 237 de novo renal transplant recipients participating in an open-label, multicenter study [Cyclosporine Avoidance Eliminates Serious Adverse Renal-toxicity (CAESAR)] investigating renal function and biopsy-proven acute rejection (BPAR) with different cyclosporine A regimens and mycophenolate mofetil. Genes were selected for their immune response and pharmacodynamic/pharmacokinetic relevance and were tested for association with BPAR. Four polymorphisms were significantly associated with BPAR. The ABCB1 2677T allele tripled the odds of developing BPAR (OR: 3.16, 95% CI [1.50-6.67]; P = 0.003), as did the presence of at least one IMPDH2 3757C allele (OR: 3.39, 95% CI [1.42-8.09]; P = 0.006). BPAR was almost fivefold more likely in patients homozygous for IL-10 -592A (OR: 4.71, 95% CI [1.52-14.55]; P = 0.007) and twice as likely in patients with at least one A allele of TNF-alpha G-308A (OR: 2.18, 95% CI [1.08-4.41]; P = 0.029). There were no statistically significant interactions between polymorphisms, or the different treatment regimens. Variation in genes of immune response and pharmacodynamic/pharmacokinetic relevance may be important in understanding acute rejection after renal transplant. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1252116
- author
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- single nucleotide polymorphism, acute rejection, kidney transplantation
- in
- Transplant International
- volume
- 21
- issue
- 9
- pages
- 879 - 891
- publisher
- Springer
- external identifiers
-
- wos:000258381400008
- scopus:49649106273
- pmid:18444945
- ISSN
- 1432-2277
- DOI
- 10.1111/j.1432-2277.2008.00679.x
- language
- English
- LU publication?
- yes
- id
- 397dfefb-233d-4281-98d3-dc5d7845ab51 (old id 1252116)
- date added to LUP
- 2016-04-01 13:28:12
- date last changed
- 2022-01-27 19:25:18
@article{397dfefb-233d-4281-98d3-dc5d7845ab51, abstract = {{Renal transplant outcomes exhibit large inter-individual variability, possibly on account of genetic variation in immune-response mediators and genes influencing the pharmacodynamics/pharmacokinetics of immunosuppressants. We examined 21 polymorphisms from 10 genes in 237 de novo renal transplant recipients participating in an open-label, multicenter study [Cyclosporine Avoidance Eliminates Serious Adverse Renal-toxicity (CAESAR)] investigating renal function and biopsy-proven acute rejection (BPAR) with different cyclosporine A regimens and mycophenolate mofetil. Genes were selected for their immune response and pharmacodynamic/pharmacokinetic relevance and were tested for association with BPAR. Four polymorphisms were significantly associated with BPAR. The ABCB1 2677T allele tripled the odds of developing BPAR (OR: 3.16, 95% CI [1.50-6.67]; P = 0.003), as did the presence of at least one IMPDH2 3757C allele (OR: 3.39, 95% CI [1.42-8.09]; P = 0.006). BPAR was almost fivefold more likely in patients homozygous for IL-10 -592A (OR: 4.71, 95% CI [1.52-14.55]; P = 0.007) and twice as likely in patients with at least one A allele of TNF-alpha G-308A (OR: 2.18, 95% CI [1.08-4.41]; P = 0.029). There were no statistically significant interactions between polymorphisms, or the different treatment regimens. Variation in genes of immune response and pharmacodynamic/pharmacokinetic relevance may be important in understanding acute rejection after renal transplant.}}, author = {{Grinyo, Josep and Vanrenterghem, Yves and Nashan, Bjoern and Vincenti, Flavio and Ekberg, Henrik and Lindpaintner, Klaus and Rashford, Michelle and Nasmyth-Miller, Clare and Voulgari, Athina and Spleiss, Olivia and Truman, Matthew and Essioux, Laurent}}, issn = {{1432-2277}}, keywords = {{single nucleotide polymorphism; acute rejection; kidney transplantation}}, language = {{eng}}, number = {{9}}, pages = {{879--891}}, publisher = {{Springer}}, series = {{Transplant International}}, title = {{Association of four DNA polymorphisms with acute rejection after kidney transplantation}}, url = {{http://dx.doi.org/10.1111/j.1432-2277.2008.00679.x}}, doi = {{10.1111/j.1432-2277.2008.00679.x}}, volume = {{21}}, year = {{2008}}, }